New hope for Tough-to-Treat skin cancer after immunotherapy fails
NCT ID NCT07472322
Summary
This study is testing a new combination of two drugs, ASTX727 (a pill) and retifanlimab (an IV infusion), for people with advanced Merkel cell carcinoma, a rare and aggressive skin cancer. It is specifically for patients whose cancer has continued to grow or spread despite receiving standard immunotherapy. The main goals are to see if this combination is safe and if it can shrink tumors or stop the cancer from progressing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MERKEL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
University of Wisconsin-Carbone Cancer Center
Madison, Wisconsin, 53792, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.